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Abstract
Background: There is increasing interest in natural treatments to control dyslipidemia and reduce
the risk of cardiovascular disease. Previous studies have demonstrated the beneficial effects of soy
yogurt fermented with Enterococcus faecium CRL 183 and of dietary isoflavones on the lipid profile.
The purpose of the present study was to investigate the effects of isoflavone-supplemented soy
yogurt, fermented with E. faecium CRL183, on lipid parameters and atherosclerosis development
in rabbits with induced hypercholesterolemia.
Methods: Forty-eight rabbits were randomly assigned to eight groups fed on the following diets
for 60 days: C - control; IY - isoflavone-supplemented soy yogurt; H - hypercholesterolemic (1.0%
cholesterol wt/wt diet); HY - hypercholesterolemic plus soy yogurt; HIY - hypercholesterolemic
plus isoflavone-supplemented soy yogurt; HP - hypercholesterolemic plus placebo; HI -
hypercholesterolemic plus isoflavone and HE - hypercholesterolemic plus pure culture of E. faecium
CRL 183. Serum lipids and autoantibodies against oxLDL (oxLDL Ab) were analyzed on days 0, 30
and 60 of the treatment and the atherosclerotic lesions were quantified at the end of the
experiment.
Results: Soy yogurt, soy yogurt supplemented with isoflavones and placebo promoted significant
reductions in total cholesterol level (38.1%, 27.0% and 26.6%, respectively). Significant increases in
serum HDL-C concentration relative to group H were detected in animals that ingested soy yogurt,
with or without the isoflavone supplement (55.2%), E. faecium culture (43.3%) or placebo (35.8%).
Intake of soy yogurt and soy yogurt supplemented with isoflavones prevented the rise of oxLDL
Ab during the study period. The extent of atherosclerosis in the thoracic and abdominal aortas was
reduced in the HIY, HY and HP groups. However, when the whole aorta was analyzed, animals
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treated with soy yogurt supplemented with isoflavones exhibited the greatest reduction (51.4%, P
< 0.05) in atherosclerotic lesion area, compared to group H.
Conclusion: Soy yogurt could be consumed as an alternative means of reducing the risk of
cardiovascular disease by improving the lipid profile and inhibiting oxLDL Ab formation. Our
findings also suggest that isoflavone supplementation may enhance the antiatherosclerotic effect of
soy yogurt.
Background
Atherosclerosis is a vascular chronic inflammation in the
arterial wall that can lead to clinical manifestations
including myocardial infarction, peripheral arterial dis-
ease and stroke [1]. Although multiple risk factors have
been shown to play a significant role in the pathogenesis
of atherosclerosis and cardiovascular disease (CVD), dysl-
ipidemia remains a major determining factor for these
pathologies. Epidemiological studies have associated high
levels of total cholesterol and LDL and reduced concentra-
tions of HDL with the risk of experiencing future cardio-
vascular events. Studies have shown that for every 1.0%
reduction in blood cholesterol there is a corresponding
2.5-3.0% reduction in the incidence of heart disease [2,3].
Additionally, oxidative modification of LDL plays an
important role in the development of atherosclerosis.
Oxidized LDLs are readily taken up by the scavenger
receptors in macrophages, leading to the formation of
foam cells, modulation of the expression of growth fac-
tors, adhesion molecules and cytokines and stimulation
of circulating monocytes. Oxidation of LDL also leads to
the formation of autoantibodies against oxidized LDL
(oxLDL), whose proatherogenic or antiatherogenic effects
have been extensively studied [4-8]. Therefore, the control
of cholesterol level and of oxidative modification of lipo-
proteins could lower the occurrence of CVD.
There is a growing interest in the dietary management of
dyslipidemias, driven by the high cost of drug therapy and
the side effects of such treatment. The dietary components
that may reduce blood cholesterol and protect against
CVD include soluble fibers, soy proteins, isoflavones and
probiotic microorganisms [9-12].
Several in vitro and in vivo studies have shown that the car-
dioprotective effects of soy isoflavones include an
improvement in serum lipid profiles [10,13] and in vascu-
lar reactivity [14], protection of LDL against oxidation
[15], modulation of cytokines and inhibition of platelet
aggregation [14].
In an in vitro experiment, we demonstrated that E. faecium
CRL183 reduces cholesterol by 53.85% [16]. We have also
reported that a soy yogurt fermented with E. faecium CRL
183 and Lactobacillus helveticus ssp jugurti 416 was able to
improve the lipid parameters in animal and human tests
[17-19]. However, during the processing of soy to produce
the soy yogurt, the total isoflavone content is reduced by
92% compared to the original level in the whole soybean
[20]. The supplementation of the soy yogurt with isofla-
vones, to bring the content to approximately that in the
whole bean, presumably reinforces the beneficial effects
of the fermented product.
To test this hypothesis, in the present study we have inves-
tigated the effects of a soy yogurt, fermented with E. fae-
cium CRL 183 and supplemented with isoflavones, on the
lipid profile and atherosclerosis development in rabbits
with diet-induced hypercholesterolemia.
Methods
Animals and experimental protocol
All studies were performed with the approval of the
Research Ethics Committee of the School of Pharmaceuti-
cal Sciences (UNESP at Araraquara, SP, Brazil).
A total of 48 New Zealand White male rabbits (from the
Central Animal Facility of Sao Paulo State University,
Botucatu, SP, Brazil), 8-9 weeks old and weighing 2.5-3.0
kg, were housed individually in temperature-controlled
rooms (22°C) with a light-dark cycle of 12:12 h.
Rabbits were randomly divided into the following eight
dietary groups (n = 6): control (C), hypercholesterolemic
(H), isoflavone-supplemented soy yogurt (IY), hypercho-
lesterolemic plus soy yogurt (HY), hypercholesterolemic
plus isoflavone-supplemented soy yogurt (HIY), hyperc-
holesterolemic plus placebo (HP), hypercholesterolemic
plus isoflavone (HI) and hypercholesterolemic plus E. fae-
cium CRL 183 (HE).
The control (C) and isoflavone-supplemented soy yogurt
(IY) groups were fed on commercial rabbit food (Nutri
Coelhos Especial, Purina, Brazil), with the following
nutritional make-up (per 100 g): 23 g protein, 4 g fats, 49
g carbohydrates, 5 g fiber and 10 g minerals. The other
groups (H, HY, HIY, HP, HI and HE) were fed on the same
rabbit diet, to which cholesterol (Sigma Chemical Co C
8503) had been added to induce hypercholesterolemia.
The level of cholesterol added to the diet was adjusted
during the experimental period (from 1.0% to 0.7% after
30 days) to maintain the health of the animal. To prepareLipids in Health and Disease 2009, 8:40 http://www.lipidworld.com/content/8/1/40
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the supplemented diet, cholesterol dissolved in ether
(ethyl ether stabilized with BHT, Carlo Erba, Italy), was
spraying onto the chow, under a hood, where it remained
for 12 h to allow the solvent to evaporate completely. The
chow was stored at -10°C for no more than 2 weeks
before use. The rabbits received restricted amounts (125
g/d) of each diet, because the extent of atherosclerosis
depends on total cholesterol intake [9]. The animals had
free access to water during the experimental period.
Groups HY, HIY, HP, HE and HI were given, by gavage
once a day, soy yogurt (2.8 mL/kg body weight), isofla-
vone-supplemented soy yogurt (2.8 mL/kg - 2.1 mg of
total isoflavone/kg body weight), placebo (2.8 mL/kg
body weight), E. faecium suspension (108 - 109 CFU) and
isoflavone (2.1 mg/kg body weight), respectively.
The soy yogurt was processed at UNISOJA (Development
and Production Unit for Soybean Derivatives) in the Food
and Nutrition Department of the School of Pharmaceuti-
cal Sciences, UNESP at Araraquara (SP, Brazil), following
the method described by Rossi et al. [17]. The conven-
tional bacterial inoculum was replaced by 3% (v/v) of a
1:1 mixture of exponential phase cultures of Enterococcus
faecium CRL 183 (probiotic microrganism) and Lactobacil-
lus helveticus ssp  jugurti  416 (fermentation adjuvant).
Chemical analysis of the product showed that 100 g pro-
vided: 86.4 kcal, 3.39 g protein, 2.74 g lipids, 12.05 g car-
bohydrates, 0.47 g ash, 81.32 g water and 5.24 mg total
isoflavones (0.98 mg daidzin, 0.37 mg glycitin, 3.72 mg
genistin, 0.04 mg daidzein, 0.04 mg glycitein and 0.09 mg
genistein). Isoflavin® (Galena, Brazil) was added to the soy
yogurt before the fermentation, at 75 mg (total isofla-
vone) per 100 g, to yield the isoflavone-supplemented soy
yogurt. Isoflavin®  contains at least 42.3% total isofla-
vones, which consist of 4.7% genistin, 11.3% genistein,
5.5% daidzin, 17.8% daidzein, 2.0% glycitin and 1.0%
glycitein. Placebo was prepared by chemical acidification
(with lactic acid) of soy yogurt basic mixture (without
bacterial culture or isoflavone). To prepare the pure cul-
ture of probiotic microorganism, E. faecium CRL 183 was
inoculated into Tryptic Soy Broth (Acumedia) and incu-
bated at 37°C for 16 hours. The cells were centrifuged at
3000 rpm for 5 minutes and the supernatant discarded.
The cells were resuspended in sterile peptone water and
the suspension was stored under refrigeration until
administered to the animals. Soy yogurt, isoflavone-sup-
plemented soy yogurt and pure culture of probiotic micro-
organism exhibited counts between 108 - 109 CFU/mL.
Isoflavone mixture was diluted in sterile water immedi-
ately before use.
All animals were fed the experimental diets for 60 days
and were weighed 3 times during the study (0, 30 and 60
days). Food intake was measured daily.
Blood Sampling
Blood was drawn from the marginal ear vein, after a 14 to
16-hour fast, on days 0, 30 and 60 of treatment. The sam-
ples were centrifuged (3500 × g for 10 min) and the serum
was taken for lipid profile determination. For the oxLDL
Ab determination, plasma was first separated from the
blood (collected into tubes containing 1.0 g/L EDTA) by
centrifugation (3500 × g for 10 min at 4°C), then 1.0
mmol/L phenylmethylsulfonyl fluoride (Sigma Chemi-
cal), 2.0 mmol/L benzamidine (Sigma Chemical), 2.0
mg/L aprotinin (Sigma Chemical) and 20.0 mmol/L BHT
(Sigma Chemical) were added to the samples of plasma.
Analysis of Serum lipids
The serum levels of TC, HDL-C and triglycerides were
assayed in each rabbit, with the aid of specific enzyme
kits. Total cholesterol was measured by the cholesterol fast
color method [21]. HDL cholesterol was estimated by first
selectively precipitating lipoproteins [22] and then apply-
ing the TC method to the supernatant. Triglycerides were
measured by the triglyceride fast color method [23]. Non-
HDL cholesterol was calculated by subtracting HDL-C
from TC and was composed of the LDL+IDL+VLDL cho-
lesterol fractions [24,25].
Detection of autoantibodies against ox LDL (oxLDL Ab)
The autoantibodies against ox LDL (oxLDL Ab) were
detected in plasma as described by Damasceno et al [5]
with modifications. Aliquots of native LDL and electron-
egative LDL were diluted in carbonate-bicarbonate buffer
(0.1 M, pH 9.4) to 1.0 μg of protein/well and used to coat
96-well ELISA microplates (Costar, Cambridge, MA, USA)
overnight at 4°C. Next, microplates were blocked with 5%
fat free milk in phosphate-buffered saline (PBS) pH 7.4,
previously inactivated by heating (100°C), and incubated
at 37°C for 30 min. After washing the plates 3 times with
PBS-Tween (0.05%), plasma samples (50 μL/well) previ-
ously diluted in PBS-1% fat free milk (1:10) were added
and plates were incubated for 2 h at room temperature.
After washing as previously described, peroxidase-conju-
gated affinity goat polyclonal anti-rabbit IgG (Rockland,
diluted 1:2000 in PBS-1% fat free milk, 50 μL/well) was
added and plates were incubated for 1.5 h at room tem-
perature. After incubation, plates were washed 3 times
with PBS-Tween (0.05%) and peroxidase substrate (0.53
mg ABTS/mL in citrate phosphate buffer pH 4.5 plus
H2O2) was added. The microplates were incubated for 30
min at room temperature and absorbance was monitored
at 405 nm with a SpectraCount® microplate photometer
(Packard BioScience Company). The intra-assay and inter-
assay variations for this ELISA were 6% and 10%, respec-
tively. Results were shown as the mean of absorbance val-
ues of triplicates with variation ≤ 10%. The data were
presented as mg/L.Lipids in Health and Disease 2009, 8:40 http://www.lipidworld.com/content/8/1/40
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Morphometric examination of lesions
At the end of the experiments, the rabbits were
heparinized and euthanized by an overdose of sodium
phenobarbital (Cristália, SP, Brazil). After euthanasia, the
liver, kidneys and heart were removed and weighed. The
aorta was removed from the aortic valve to the iliac bifur-
cation to analyze the atherosclerotic lesions. The aorta was
divided into two segments, comprising: 1) aortic arch; 2)
thoracic aorta and abdominal aorta. The material was
fixed in 10% neutral buffered formaldehyde (overnight,
37°C), rinsed with saline solution and stained with Sudan
IV to visualize areas of atherosclerotic plaque [26]. The
stained aorta was photographed with a digital camera
(Sony) and the sudanophilic lesions were identified and
quantified. The surface area of the atherosclerotic lesions
was measured with an image analyzer system (Imagelab -
USP, Brazil) and expressed as the percentage of the total
surface area of the aortic intima covered by lesion.
Statistical analysis
Quantitative results were reported as mean ± SEM. The
data were tested by analysis of variance (ANOVA) and the
means were compared across groups by the Tukey test, sig-
nificance being declared when P ≤ 0.05. All analyses were
carried out with the BIOSTAT statistical package.
Results
Food intake, weight gain and organ weight
Food intake was reduced in the animals of groups HIY and
HI, without differing significantly from placebo (HP) or
E. faecium (HE) - treated animals. Despite differences in
food intake, the weight gain showed no difference
between groups (P < 0.05). The rabbits fed only a hyperc-
holesterolemic diet (group H) showed the highest weights
for liver, heart and kidneys (Table 1).
Effects on serum lipids
The effects of treatments on serum lipids are shown in
Table 2. All animals had comparable serum levels of TC,
HDL-C and n-HDL-C at the beginning of the experiment.
After 30 days, group H showed the highest concentrations
of TC and n-HDL-C, without differing from groups HIY,
HP and HE. The rabbits that received soy yogurt exhibited
the greatest reduction (P < 0.05) in TC (32.8%) and n-
HDL-C (33.2%), relative to group H. Isoflavones lowered
the TC and n-HDL-C levels by 19.5% and 19.8%, respec-
tively. At the end of the experiment - 30 days after the
reduction of the cholesterol added to the chow (from 1%
to 0.7%) - groups H, HE and HI showed the highest TC
and n-HDL-C concentrations without differing among
themselves. Soy yogurt, soy yogurt supplemented with
isoflavones and placebo promoted significant reductions
in TC level (38.1%, 27.0% and 26.6% respectively).
HDL-C concentration was lower (P < 0.05) in the animals
of groups H, HY, HP and HI, after 30 days of treatment.
On the other hand, rabbits in HIY, IY and HE showed lev-
els of HDL-C significantly higher (46.1%, 44.1% and
34.3%, respectively) than group H and similar to the con-
trol. At the end of the study, a significant increase in HDL-
C was detected in animals that received the soy yogurt,
with or without isoflavone supplement (55.2%), probi-
otic microorganism (43.3%) or placebo (35.8%), relative
to group H. After 60 days of study, groups HIY, HP and HE
had lower triglyceride levels (P < 0.05) than group H.
Autoantibodies against oxLDL (oxLDL Ab)
Animals that received soy yogurt exhibited lower concen-
trations of oxLDL Ab (P < 0.05) than group H, after 30
days of treatment. At the end of the experiment, oxLDL Ab
was significantly higher (P < 0.05) in group H (Table 3).
The oxLDL Ab level was also compared with the baseline
value (T0) for each animal group (Figure 1). The rabbits
fed a high cholesterol diet (H), placebo (HP) and isofla-
vone mixture (HI) exhibited a rapid rise in oxLDL Ab (P <
0.05), while soy yogurt and soy yogurt supplemented with
isoflavones reduced the percent increase of this parameter
during the course of the experiment. Interestingly, the E.
Table 1: Effects of different treatments on food intake, body weight and organ weight in the rabbits
Groups* Food Intake (g) Weight gain (g) Liver (g) Heart (g) Kidney (g)
C 125.00 ± 0.00a 903.05 ± 124.86a 83.17 ± 3.92d 5.78 ± 0.20b 6.59 ± 0.52d
IY 125.00 ± 0.00a 760.08 ± 44.16a 97.22 ± 8.39cd 6.06 ± 0.24ab 7.47 ± 0.10c
H 124.93 ± 0.50a 713.40 ± 39.75a 165.90 ± 3.41a 7.06 ± 0.56a 10.02 ± 0.72a
HIY 113.76 ± 24.90b 738.68 ± 144.36a 111.44 ± 7.21c 6.69 ± 0.48ab 7.67 ± 0.33cd
HY 122.57 ± 8.19a 680.50 ± 64.23a 146.08 ± 2.51ab 6.55 ± 0.16ab 8.39 ± 0.28b
HP 119.46 ± 10.21ab 824.50 ± 95.87a 134.61 ± 3.12bc 6.84 ± 0.06ab 9.30 ± 0.14a
HE 118.17 ± 9.92ab 810.57 ± 95.22a 110.12 ± 7.53c 6.24 ± 0.39ab 7.21 ± 0.46cd
HI 110.14 ± 17.52b 851.88 ± 67.04a 98.22 ± 6.07cd 5.73 ± 0.22b 7.36 ± 0.74cd
Values represent mean ± SEM (n = 6).
Statistical comparison of groups: means with identical letters in the same column do not differ significantly (P ≤ 0.05).
* C = control; IY = isoflavone-supplemented soy yogurt; H = hypercholesterolemic; HIY = hypercholesterolemic plus isoflavone-supplemented soy 
yogurt; HY = hypercholesterolemic plus soy yogurt; HP = hypercholesterolemic plus placebo; HE = hypercholesterolemic plus E.faecium; HI = 
hypercholesterolemic plus isoflavone.Lipids in Health and Disease 2009, 8:40 http://www.lipidworld.com/content/8/1/40
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faecium suspension increased the oxLDL Ab in the first 30
days (P < 0.05), but during the later period of treatment
the concentration fell to a level near those of groups C, IY,
HIY and HY (Figure 1).
Sudanophilic lesions in rabbits aortas
Comparisons of cross-sectional atherosclerotic lesion area
in aortic segments are shown in Figure 2. All rabbits on the
cholesterol-enriched diet developed atherosclerosis. In
contrast, no animals fed a normal diet developed athero-
sclerotic lesions. No significant difference was observed in
the lesion area in the aortic arch (%), relative to group H.
The extent of atherosclerosis in the thoracic and abdomi-
nal aorta was reduced in groups HIY, HY and HP. How-
ever, when the whole aorta was analyzed, animals treated
with soy yogurt supplemented with isoflavones exhibited
the greatest reduction (51.4% compared to group H, P <
0.05) in atherosclerotic lesion area, without differing
from HY and HP groups (40.8% and 13.9%, respectively,
compared to group H, P > 0.05).
Discussion
Dietary changes are recommended as the first line of inter-
vention for moderate dyslipidemia. This study evaluated
the potential cardiovascular protective effects of an isofla-
vone-supplemented soy yogurt. We also investigated the
isolated contributions of the probiotic microrganism and
isoflavones to the observed effects.
Feeding excessive amounts of cholesterol to rabbits
induces rapid development of hyperlipidemia and athero-
sclerosis [9,27,28]. In this study, the cholesterol added to
the diet induced hypercholesterolemia in all experimental
groups and none of the treatments applied to these groups
reduced the serum lipids to basal levels.
In this study, we observed a decrease in the total (26.6%)
and non-HDL cholesterol (27.8%) in rabbits fed the pla-
cebo product (unfermented soy product), suggesting that
the ingredients of the soy yogurt mixture may contribute
to this effect. The ingredients used to obtain the placebo
Table 2: Serum lipid levels in rabbits during the experiment.
Time C IY H HIY HY HP HE HI
TC
Initial 49.0 ± 3.7a 42.0 ± 4.4a 42.0 ± 2.8a 44. 5 ± 5.4a 45.3 ± 5.1a 44.8 ± 5.8a 46.3 ± 2.7a 46.0 ± 1.9a
T30 63.3 ± 4.3d 59.3 ± 6.6d 3650.0 ± 
138.0a
3517.5 ± 
159.9a
2452.5 ± 
277.5c
3380.0 ± 
189.9ab
3413.5 ± 
192.7a
2938.5 ± 
154.5b
T60 53.3 ± 6.2c 43.5 ± 4.4c 2556.5 ± 
120.3a
1867.5 ± 
251.7b
1583.8 ± 86.3b 1876.3 ± 
233.6b
2605.0 ± 
166.2a
2327.5 ± 71.5a
HDL-C
Initial 31.5 ± 2.3a 29.8 ± 2.2a 28.5 ± 2.5a 31.8 ± 1.1a 32.0 ± 2.6a 31.5 ± 3.6a 30.3 ± 1.5a 29.8 ± 1.9a
T30 38.3 ± 2.1a 36.8 ± 3.8ab 25.5 ± 0.9c 37.3 ± 2.4ab 31.0 ± 2.2bc 32.0 ± 2.5abc 34.3 ± 2.7ab 30.8 ± 1.8bc
T60 26.8 ± 2.8a 27.0 ± 1.7a 16.8 ± 2.8c 26.0 ± 2.1a 26.0 ± 1.7a 22.8 ± 2.8ab 24.0 ± 1.9a 20.5 ± 2.1bc
n-HDL-C
Initial 17.5 ± 2.6a 12.3 ± 2.8a 13.5 ± 2.9a 12.8 ± 2.3a 13.3 ± 3.0a 13.3 ± 2.4a 16.0 ± 2.0a 16.3 ± 1.92a
T30 25.0 ± 2.6d 22.5 ± 2.9d 3624.5 ± 
138.0a
3480.3 ± 
162.2a
2421.5 ± 
278.5c
3348.0 ± 
187.4ab
3379.3 ± 
193.1a
2907.8 ± 
154.5b
T60 26.5 ± 4.4c 16.5 ± 2.5c 2539.8 ± 
120.2a
1841.5 ± 
249.8b
1557.8 ± 86.6b 1853.5 ± 
231.8b
2581.5 ± 
166.2a
2307.0 ± 71.3a
TGL
Initial 90.0 ± 5.3ab 68.5 ± 12.8b 66.0 ± 7.3b 65.8 ± 7.2b 61.5 ± 8.9b 59.3 ± 4.4b 99.5 ± 9.5a 99.3 ± 9.2a
T30 57.5 ± 2.9e 83.5 ± 4.2de 260.3 ± 9.4a 145.5 ± 27.5c 245.3 ± 17.6ab 262.0 ± 31.8a 122.8 ± 20.4cd 203.3 ± 3.6b
T60 53.0 ± 4.5d 61.0 ± 7.3d 245.5 ± 25.9a 70.5 ± 3.9d 235.0 ± 27.7a 192.0 ± 12.3b 115.8 ± 6.4c 215.0 ± 7.1ab
Values (in mg/dL) represent mean ± SEM (n = 6). Statistical comparison of groups: means with identical letters on the same line do not differ 
significantly (P ≤ 0.05).
C = control; IY = isoflavone supplemented soy yogurt; H = hypercholesterolemic; HIY = hypercholesterolemic plus isoflavone-supplemented soy 
yogurt; HY = hypercholesterolemic plus soy yogurt; HP = hypercholesterolemic plus placebo; HE = hypercholesterolemic plus E.faecium; HI = 
hypercholesterolemic plus isoflavone.
TC = Total Cholesterol; HDL-C = High Density Lipoprotein; n-HDL-C = non - High Density Lipoprotein; TGL = Triglycerides.Lipids in Health and Disease 2009, 8:40 http://www.lipidworld.com/content/8/1/40
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and the soy yogurt included, in each 100 g, 3.39 g of soy
protein and 5.24 mg of total isoflavones, components that
have potential cholesterol-reducing effects [29].
Though no significant differences were observed in TC or
n-HDL-C levels of animals treated with placebo, soy
yogurt and isoflavone-supplemented soy yogurt, the
product fermented with E. faecium CRL 183 promoted the
greatest reduction (P > 0.05) in TC and non-HDL-C
(38.1% and 38.7%, respectively). The supplementation of
soy yogurt with isoflavones did not enhance its hypolipi-
demic effect. In an earlier investigation of our group,
using rabbits with diet-induced hypercholesterolemia, the
serum TC content was reduced about 18% by ingestion of
the unsupplemented soy yogurt [18]. In another study,
rats fed fermented soy product enriched with isoflavones
had significantly lower (P < 0.05) serum total cholesterol
(15.5%) than rats fed on a hypercholesterolemic diet.
Non-HDL cholesterol was lower (P < 0.05) in the rats fed
fermented soy product, with (27.4%) or without (23.2%)
added isoflavones, than in untreated hypercholestero-
lemic rats [30].
In a previous study, E. faecium CRL 183 reduced the cho-
lesterol by 54% in an in vitro model [16]. However, the
results of the present study did not confirm this effect in
rabbits. The E. faecium culture did not promote any
improvement in TC or n-HDL-C, indicating that the pro-
biotic microrganism alone was not responsible for the
beneficial effects of soy yogurt on these lipid fractions.
Epidemiological studies have demonstrated that HDL-C is
a strong, independent, inverse predictor of cardiovascular
disease risk [31-33]. The soy yogurt, supplemented or not
with isoflavones, placebo and the E. faecium culture pre-
vented the reduction of HDL-C levels, relative to the con-
trol group, and raised the HDL-C concentration relative to
group H. The probiotic microorganism (E. faecium CRL
183) seems to be decisive for the improvement of the
HDL-C level, since in the placebo group the reduction of
this fraction in the blood was higher. In a previous exper-
iment with rabbits, the HDL-C level increased 17.8% in
the group that consumed the fermented product [18].
Also, the same fermented product, without isoflavone
supplementation, was capable of raising the HDL-C level
by 10% in normocholesterolemic men [19]. The increase
of HDL-C could be an important health benefit of soy
yogurt, since each 1-mg increase in HDL-C is associated
with an estimated 2-3% reduction in cardiovascular risk
[34].
The triglycerides level varied (P < 0.05) between groups at
the beginning of the study, probably because of high bio-
logical variability of this lipid. In the current study, rabbits
fed the pure culture of E. faecium, soy yogurt supple-
mented with isoflavones or placebo showed triglycerides
concentrations significant lower, after 60 days on these
diets. In a previous study with the same fermented prod-
uct, with or without isoflavones, no effect on triglycerides
levels was detected [18,19,30].
The differences in the magnitude of the observed effects
on blood lipid levels, between the present and earlier
studies that evaluated the same soy yogurt, might be
explained by differences in experimental design. An
important difference between the previous and present
studies is the cholesterol concentration added to the diet
to induce hypercholesterolemia and atherosclerosis. Rossi
et al. [18] induced hypercholesterolemia by feeding the
rabbits a cholesterol-enriched diet (0.15% wt/wt) during
the first 15 days of the experiment. In the present study,
rabbits were fed a cholesterol-enriched diet for the entire
60 days (1% wt/wt during the first 30 days and 0.7% wt/
wt thereafter) to induce atherosclerotic lesions. The TC
concentration of group H after this time was about 11 -
fold higher than that observed in the earlier study and this
could influence the effect of the soy yogurt on lipid
parameters.
There are numerous reports showing the hypocholestero-
lemic effects of probiotics. Xiao et al [12] showed in rats
that milk fermented with Bifidobacterium longum BL1
reduced the total and LDL cholesterol, while no change in
HDL-C concentration was observed. Paik et al [11] found
that Bacillus polyfermenticus SCD reduced plasma LDL-C
and triglycerides in rats after 6 weeks of treatment. The
mechanisms involved in the reduction of serum choles-
terol by probiotics, although not completely known,
include deconjugation of bile salts, cholesterol assimila-
Table 3: Variation in levels of autoantibodies against oxLDL in 
plasma of rabbits.
Groups* Oxidized LDL autoantibodies (mg/L)
T0 T30 T60
C 0.204 ± 0.104a 0.228 ± 0.140b 0.316 ± 0.156b
IY 0.272 ± 0.138a 0.407 ± 0.137ab 0.409 ± 0.137b
H 0.338 ± 0.166a 0.821 ± 0.284a 1.809 ± 0.514a
HIY 0.338 ± 0.166a 0.531 ± 0.267ab 0.530 ± 0.232b
HY 0.390 ± 0.289a 0.391 ± 0.097b 0.553 ± 0.296b
HP 0.323 ± 0.105a 0.671 ± 0.223ab 0.799 ± 0.285b
HE 0.171 ± 0.050a 0.550 ± 0.243ab 0.354 ± 0.177b
HI 0.220 ± 0.089a 0.527 ± 0.085ab 0.556 ± 0.111b
Values (in mg/dL) represent mean ± SEM (n = 6). Statistical 
comparison of groups: means with identical letters in the same 
column do not differ significantly (P ≤ 0.05). *C = control; IY = 
isoflavone supplemented soy yogurt; H = hypercholesterolemic; HIY 
= hypercholesterolemic plus isoflavone-supplemented soy yogurt; HY 
= hypercholesterolemic plus soy yogurt; HP = hypercholesterolemic 
plus placebo; HE = hypercholesterolemic plus E.faecium; HI = 
hypercholesterolemic plus isoflavone.Lipids in Health and Disease 2009, 8:40 http://www.lipidworld.com/content/8/1/40
Page 7 of 10
(page number not for citation purposes)
tion by probiotic cells and fermentation of indigestible
carbohydrates from the diet to produce short-chain fatty
acids [35,36]. The lipid profile effects observed here prob-
ably involve the ingredients of soy yogurt, the probiotic
microorganism and its bioactive metabolites.
The isoflavone mixture reduced the TC and n-HDL-C
(19.5%) after 30 days of feeding. However, this effect was
not maintained until the end of the protocol. Several stud-
ies have assessed isoflavones as a hypocholesterolemic
agent and the results are contradictory. Antony et al
[37,38] showed that soy protein without isoflavones was
less effective at lowering blood cholesterol levels and pre-
venting the development of atherosclerosis in monkeys
than isoflavone-rich soy protein. In contrast, Adams et al
[39] showed that monkeys fed a soy protein diet with low
isoflavone content exhibited a lipid profile similar to
those fed a similar diet high in isoflavones. Wilson et al
[40] observed that soy protein, with or without isofla-
vones, lowered TC and n-HDL-C concentrations in ham-
sters.
The association between oxidized LDL, hypercholestero-
lemia and atherosclerosis has been demonstrated in
numerous studies in animals and humans [15,41]. Oxida-
tive modification of LDL induces the formation of immu-
nogenic epitopes in the LDL, leading to the generation of
antibodies against oxidized LDL (oxLDL Ab) [42]. In this
study, the formation of autoantibodies against ox LDL
was higher (P < 0.05) in the hypercholesterolemic group
(H) by the end of the treatment and the intake of soy
yogurt, supplemented with isoflavones or not, prevented
this rise in oxLDL Ab during the experiment. The reduc-
tion in non-HDL-C concentrations (LDL+VLDL+IDL),
with a consequent reduction in LDL particles available for
oxidation, observed in the HY and HIY groups could, par-
tially, explain this effect.
The importance of autoantibodies against oxLDL in
atherogenesis remains controversial because of the com-
plexity of oxLDL Ab system [4]. An atherogenic role was
supported by studies that found elevated concentrations
of oxLDL Ab in patients with atherosclerosis [43-45].
Conversely, other studies found an inverse relation
between autoantibodies and atherosclerosis development
[4,46]. Analyzing the whole aorta of the rabbits, we
observed that only soy yogurt supplemented with isofla-
vones reduced the atherosclerosis. The variables analyzed
in this study are insufficient to define the exact causes or
mechanisms involved in the antiatherogenic effect of the
soy yogurt. However, given that atherosclerosis is a
chronic immune inflammatory disease, it is possible that
increase in levels of antibodies against oxidized LDL in the
H, HP, HE and HI groups is linked to the development of
the atherosclerotic lesion. On the other hand, the results
indicate that the soy yogurt supplemented with isofla-
vones had an atheroprotective effect that may include the
anti inflammatory properties of the probiotic product
already described [47] and the antioxidant effect of isofla-
vones [14].
Conclusion
In conclusion, this study showed that the soy yogurt could
be used as an alternative means of reducing the risk of car-
diovascular diseases by increasing HDL-C, lowering total
cholesterol and n-HDL-C and inhibiting oxLDL Ab forma-
tion. Our findings also suggest that isoflavone supple-
mentation may enhance the antiatherosclerotic effect of
the soy yogurt.
Abreviations
CVD: Cardiovascular Disease; (C): control group; (H):
hypercholesterolemic group; (IY): isoflavone-supple-
mented soy yogurt group; (HY): hypercholesterolemic
plus soy yogurt group; (HIY): hypercholesterolemic plus
isoflavone-supplemented soy yogurt group; (HP): hyperc-
holesterolemic plus placebo group; (HI): hypercholester-
olemic plus isoflavone group; (HE): hypercholesterolemic
plus  E.faecium  CRL 183 group; TC: Total Cholesterol;
HDL-C: High Density Lipoprotein Cholesterol; LDL-C:
Low Density Lipoprotein Cholesterol; VLDL: Very Low
Density Lipoprotein Cholesterol; n-DHL-C: Non High
Density Lipoprotein Cholesterol; oxLDL: oxidized Low
Density Lipoprotein; oxLDL Ab: Autoantibodies against
oxidized Low Density Lipoprotein.
Changes in autoantibodies against oxLDL (percentage) in  plasma of rabbits, compared with the baseline levels Figure 1
Changes in autoantibodies against oxLDL (percent-
age) in plasma of rabbits, compared with the baseline 
levels. Values are means, n = 6. * Significantly different from 
day 0 (P < 0.05). C = control; IY = isoflavone supplemented 
soy yogurt; H = hypercholesterolemic; HIY = hypercholeste-
rolemic plus isoflavone-supplemented soy yogurt; HY = 
hypercholesterolemic plus soy yogurt; HP = hypercholester-
olemic plus placebo; HE = hypercholesterolemic plus E.fae-
cium; HI = hypercholesterolemic plus isoflavone.
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Percentage of aortic area - A = arch segment; B = thoracic and abdominal segments; C = whole aorta - covered with lesion Figure 2
Percentage of aortic area - A = arch segment; B = thoracic and abdominal segments; C = whole aorta - covered 
with lesion. The bar graphs represent the average (n = 6) for each group with standard errors. H = hypercholesterolemic; 
HIY = hypercholesterolemic plus isoflavone-supplemented soy yogurt; HY = hypercholesterolemic plus soy yogurt; HP = 
hypercholesterolemic plus placebo; HE = hypercholesterolemic plus E.faecium; HI = hypercholesterolemic plus isoflavone.
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